Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors

This study will test the safety, tolerability, and pharmacokinetics of VP301 in patients with relapsed or refractory multiple myeloma, lymphoma, or solid tumors.

Inclusion Criteria:Histologic diagnosis of a refractory solid tumor, refractory myeloma or lymphoma with measurable or evaluable diseasePatients must have progressed following all therapies of known, potential clinical benefit, or for whom treatments of known clinical benefit are contraindicated.Adequate kidney, liver, and hematologic functionEastern Cooperative Oncology Group (ECOG) performance status 0 to 2Exclusion Criteria:Active brain metastases and history of leptomeningeal metastases.Myeloma patients with plasmacytoma as only measurable diseaseNon-secretory myelomaPatients with advanced metastatic, symptomatic, visceral spread who are at risk of life-threatening complicationsActive or chronic, uncontrolled bacterial, viral, or fungal infection(s)Abnormal ECGHas clinically significant cardiovascular diseaseAdditional active malignancy that may confound the assessment of the study endpointsPregnancy or lactationKnown seropositivity for HIV (human immunodeficiency virus) or active hepatitis B or hepatitis C